Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Loading Pathway...

GABAA receptor Gamma- aminobutyric acid type B receptor N-type calcium channel potassium voltage-gated channel subfamily J Adenylate cyclase type 2 Kappa-type opioid receptor Gβ Gγ Guanine nucleotide- binding protein G(i) subunit alpha-1 γ-Aminobutyric acid Dezocine cAMP Ca+ Ca+ Na+ Na+ γ-Aminobutyric acid Dezocine Dezocine ATP PPi GTP Pain Magnesium More GABA leads to inhibition of dopamine cell firing in the spinal cord pain transmission neurons, as well as the inhibition of dopamine cell firing in the reward system of the brain. Increased calcium levels lead to increased neurotransmitter release. GABA is released by synaptic vesicles. Dezocine antagonizes kappa opioid receptors in the spinal cord and the cerebral cortex The kappa opioid receptor through the gamma subunit inhibits voltage gated N-type calcium channels, stopping the influx of calcium into the neuron Post-Synaptic Neuron Pre-Synaptic Neuron Synapse Cytosol Synaptic Vesicle With the kappa opioid receptor unable to inhibit adenylate cyclase, it is able to synthesize cAMP which increases the excitability in spinal cord pain transmission neurons. Diffusion The inhibition of the Gi subunit of the kappa opioid receptor prevents the activation of inwardly rectifying potassium channel increasing potassium and sodium conductance. This prevents hyperolarization Kappa opioid inhibition by Dezocine mainly occurs in the spinal cord and cerebral cortex
GABRG2 GABBR1 CACNB1 KCNJ9 ADCY2 OPRK1 GNB1 GNG2 GNAI1 γ-Aminobutyric acid Dezocine cAMP Calcium Calcium Sodium Sodium γ-Aminobutyric acid Dezocine Dezocine Adenosine triphosphate Pyrophosphate Guanosine triphosphate Pain
GABRG2 GABBR1 CACNB1 KCNJ9 ADCY2 OPRK1 GNB1 GNG2 GNAI1